Absci Corporation

Equities

ABSI

US00091E1091

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
5.46 USD +5.81% Intraday chart for Absci Corporation +16.42% +30.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai CI
Transcript : Absci Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
HC Wainwright Raises Absci's Price Target to $7 From $4, Buy Rating Kept MT
Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference CI
Absci, PrecisionLife to Develop AI-Enabled Drug Pipeline MT
Sector Update: Health Care MT
Absci Corporation and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline CI
Absci Corporation(NasdaqGS:ABSI) dropped from NASDAQ Biotechnology Index CI
Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024 CI
KeyBanc Initiates Absci at Overweight With $3 Price Target, Calls Valuation 'Attractive' Given New Drug Programs, Partnerships MT
AstraZeneca: AI collaboration with Absci CF
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday MT
Sector Update: Health Care MT
Absci Working With AstraZeneca to Use AI Platform to Discover Oncology Candidate MT
Absci Corporation Announces Collaboration with Astrazeneca to Advance Ai-Driven Oncology Candidate CI
UK Stocks-Factors to watch on Dec 4 RE
AstraZeneca, Absci Enter $247 Million Partnership to Develop New Cancer Treatment MT
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT RE
AstraZeneca ties up with AI biologics company to develop cancer drug - FT RE
North American Morning Briefing : Stocks Seen -2- DJ
Absci's Q3 Net Loss Narrows, Revenue Falls MT
Earnings Flash (ABSI) ABSCI CORPORATION Reports Q3 Revenue $744,000 MT
Absci Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Almirall Teams Up with Absci on AI-designed Dermatological Disease Treatments MT
Chart Absci Corporation
More charts
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. The Company applies generative AI to design optimal drug candidates based on target affinity, safety, manufacturability, and other traits.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.46 USD
Average target price
6.373 USD
Spread / Average Target
+16.73%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW